Omrix Biopharmaceuticals, a developer of biosurgical and passive immunotherapy products, plans to offer 3.4 million shares at a range of $15 to $17. UBS Investment Bank and CIBC World Markets head the list of underwriters on the deal. Timing has yet to be determined.
